Table 1.
Clinical studies for the treatment of cancer with IL-8 and IL-8 receptor antagonist agents
| IL-8 Agent | Title of Clinical Trial | Clinical Trial Number* | Status |
|---|---|---|---|
| IL-8 | |||
| HuMax-IL8 (BMS-986253) |
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | NCT03689699 | R |
| HuMax-IL8 (BMS-986253) |
A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 or Cabiralizumab in Advanced Hepatocellular Carcinoma (HCC) Patients | NCT04050462 | R |
| HuMax-IL8 (BMS-986253) |
Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | NCT04123379 | R |
| HuMax-IL8 (BMS-986253) |
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination With Nivolumab in Patients With Advanced Cancers | NCT03400332 | A |
| HuMax-IL8 (BMS-986253) |
HuMax-IL8 (Interleukin-8) in Patients With Advanced Malignant Solid Tumors | NCT02536469 | C |
| IL-8 Receptor | |||
| SX-682 | SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy | NCT04245397 | R |
| SX-682 | SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab | NCT03161431 | R |
| SX-682 | A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | NCT04477343 | NR |
| AZD5069 | Combination Study of AZD5069 and Enzalutamide | NCT03177187 | R |
| AZD5069 | Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck | NCT02499328 | A |
| AZD5069 | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | NCT02583477 | C |
| Navarixin | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | NCT03473925 | A |
(*)
www.clinicaltrials.gov; R= recruiting; NR= not yet recruiting; A= active; C= completed as of August 6, 2020.